Glioz 100 Capsule contains Temozolomide 100 mg, an oral alkylating agent primarily indicated for the treatment of certain types of brain tumors, including glioblastoma multiforme and anaplastic astrocytoma. Temozolomide exerts its antineoplastic effect by methylating DNA at the O6 and N7 positions of guanine residues, leading to DNA strand breaks and apoptosis in rapidly dividing tumor cells. Glioz 100 is typically administered as part of a chemotherapy regimen either concomitantly with radiotherapy or as maintenance therapy following initial treatment. The capsule formulation allows for convenient oral administration, improving patient compliance. Dosage and treatment schedules should be individualized based on patient weight, hematologic status, and overall clinical condition, with regular monitoring of blood counts due to the risk of myelosuppression, including neutropenia and thrombocytopenia. Common adverse effects include nausea, vomiting, fatigue, and hematologic toxicities, while rare but serious complications such as opportunistic infections and hepatotoxicity may occur. Glioz 100 should be used under strict medical supervision, with appropriate supportive care measures and periodic laboratory evaluations to optimize therapeutic outcomes and minimize toxicity. It is contraindicated in patients with known hypersensitivity to Temozolomide or other alkylating agents.